Public Employees Retirement Association of Colorado reduced its holdings in Amgen, Inc. (NASDAQ:AMGN) by 0.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 576,384 shares of the medical research company’s stock after selling 1,564 shares during the quarter. Public Employees Retirement Association of Colorado owned about 0.10% of Amgen worth $111,536,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Parkside Financial Bank & Trust boosted its position in shares of Amgen by 2.6% during the third quarter. Parkside Financial Bank & Trust now owns 1,883 shares of the medical research company’s stock valued at $364,000 after buying an additional 47 shares during the last quarter. Clear Harbor Asset Management LLC boosted its position in shares of Amgen by 0.8% during the third quarter. Clear Harbor Asset Management LLC now owns 6,385 shares of the medical research company’s stock valued at $1,236,000 after buying an additional 49 shares during the last quarter. Carlton Hofferkamp & Jenks Wealth Management LLC boosted its position in Amgen by 1.1% in the third quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 4,694 shares of the medical research company’s stock worth $933,000 after purchasing an additional 50 shares during the last quarter. Independence Bank of Kentucky boosted its position in Amgen by 3.5% in the third quarter. Independence Bank of Kentucky now owns 1,645 shares of the medical research company’s stock worth $318,000 after purchasing an additional 55 shares during the last quarter. Finally, Carroll Financial Associates Inc. boosted its position in Amgen by 0.8% in the second quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock worth $1,370,000 after purchasing an additional 58 shares during the last quarter. Institutional investors and hedge funds own 76.33% of the company’s stock.
In other news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $193.58, for a total value of $387,160.00. Following the completion of the transaction, the director now directly owns 16,436 shares in the company, valued at approximately $3,181,680.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Cynthia M. Patton sold 13,426 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $208.07, for a total value of $2,793,547.82. Following the completion of the transaction, the senior vice president now owns 32,648 shares of the company’s stock, valued at $6,793,069.36. The disclosure for this sale can be found here. Insiders sold a total of 17,851 shares of company stock valued at $3,685,674 over the last quarter. Company insiders own 0.25% of the company’s stock.
Shares of AMGN traded up $3.12 during mid-day trading on Friday, hitting $221.11. The stock had a trading volume of 2,069,900 shares, compared to its average volume of 2,911,719. The business has a fifty day moving average price of $202.75 and a 200-day moving average price of $188.90. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $221.25. The company has a debt-to-equity ratio of 2.54, a current ratio of 2.89 and a quick ratio of 2.59. The firm has a market cap of $127.80 billion, a P/E ratio of 15.35, a PEG ratio of 2.21 and a beta of 1.09.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.53 by $0.13. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.63 billion. During the same period in the prior year, the business earned $3.69 EPS. The company’s revenue for the quarter was down 2.8% compared to the same quarter last year. As a group, research analysts expect that Amgen, Inc. will post 14.44 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 6th. Stockholders of record on Friday, November 15th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.62%. The ex-dividend date of this dividend is Thursday, November 14th. Amgen’s payout ratio is currently 40.28%.
Several research analysts have weighed in on the company. Leerink Swann boosted their price objective on Amgen from $189.00 to $205.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Morgan Stanley cut their price objective on Amgen from $211.00 to $207.00 and set an “overweight” rating on the stock in a research report on Monday, July 15th. BidaskClub raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Royal Bank of Canada reissued a “hold” rating on shares of Amgen in a research report on Monday, September 30th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $225.00 price objective (up previously from $202.00) on shares of Amgen in a research report on Friday, August 16th. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Amgen has a consensus rating of “Buy” and an average price target of $219.56.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Channel Trading
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.